The design and application of DNA chips for early detection of SARS-CoV from clinical samples.
Yi-Ming Zhou,Ren-quan Yang,Sheng-ce Tao,Ze Li,Qiong Zhang,Hua-fang Gao,Zhi-wei Zhang,Jian-yu Du,Pei-xuan Zhu,Li-li Ren,Liang Zhang,Dong Wang,Lan Guo,Yan-bin Wang,Yong Guo,Yan Zhang,Chuan-zan Zhao,Can Wang,Di Jiang,Yan-hua Liu,Hua-wei Yang,Li Rong,Yan-jun Zhao,Shuang An,Zhe Li,Xiao-dong Fan,Jian-wei Wang,Yun Cheng,Ou Liu,Zhong Zheng,Huan-cong Zuo,Quan-zhong Shan,Li Ruan,Zhan-xiu Lü,Tao Hung,Jing Cheng
DOI: https://doi.org/10.1016/j.jcv.2004.10.019
IF: 14.481
2005-01-01
Journal of Clinical Virology
Abstract:SARS coronavirus has been identified as the cause of severe acute respiratory syndrome (SARS). Few tests allow confirmation or exclusion of SARS within the first few days of infection. A gene chip is a useful tool for the study of microbial infections mainly for its capability of performing multi-target analysis in a single test.Investigate the possibility of early detection of SARS virus from clinical samples using the gene chip-based method.We purified RNA from SARS-CoV obtained from routinely collected peripheral blood and sputum samples of 34 patients who had been identified as probable SARS patients by following the interim U.S. case definition. Four segments of the SARS-CoV were amplified using reverse transcription-nested PCR and the products examined using the 70-mer gene chips for SARS-CoV detection.A blind-test of both peripheral blood and sputum specimens lead to the positive detection of SARS-CoV in 31 out of 34 patients. SARS-CoV was not found in peripheral blood or sputum specimens from three patients. Two of the 34 patients were only 3 days post-onset of symptoms and were subsequently confirmed to be SARS positive. Our results indicate that the gene chip-based molecular test is specific for SARS-CoV and allows early detection of patients with SARS with detection rate about 8% higher than the single PCR test when the sputum sample is available.